Replicate Bioscience develops self-replicating RNA (srRNA) immunotherapies to prevent and reverse drug resistance in cancer treatments. Their platform enhances protein expression within cells, enabling the detection and elimination of cancerous cells while improving the effectiveness of immuno-oncology therapies.
Funding
$53M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing treatments, including immunotherapies, limiting their long-term effectiveness. Current immuno-oncology approaches may fail to generate a sufficient immune response to eliminate cancerous cells, leading to disease progression.
Solution
Replicate Bioscience is developing self-replicating RNA (srRNA) immunotherapies designed to overcome and reverse drug resistance in cancer. Their platform utilizes next-generation srRNA vectors that, once inside cells, drive repeated production of natural RNA. This process results in enhanced protein expression, which amplifies the immune system's ability to detect and eliminate cancerous cells. By improving protein expression within cells, Replicate Bioscience aims to enhance the effectiveness of immuno-oncology therapies and provide more durable treatment outcomes. The srRNA approach allows for broad application across multiple therapeutic areas.
Target Audience
The primary target audience includes patients with cancers that have developed resistance to existing treatments, as well as healthcare providers and researchers in the fields of oncology and immunology.
Features
- Next-generation self-replicating RNA (srRNA) vector technology for enhanced and durable protein expression.
- srRNA-driven repeated production of natural RNA within cells.
- Broad pipeline of srRNA treatments spanning infectious disease, oncology, and autoimmune disorders.